JP2024532482A - 免疫活性を刺激するための方法および組成物 - Google Patents

免疫活性を刺激するための方法および組成物 Download PDF

Info

Publication number
JP2024532482A
JP2024532482A JP2024513926A JP2024513926A JP2024532482A JP 2024532482 A JP2024532482 A JP 2024532482A JP 2024513926 A JP2024513926 A JP 2024513926A JP 2024513926 A JP2024513926 A JP 2024513926A JP 2024532482 A JP2024532482 A JP 2024532482A
Authority
JP
Japan
Prior art keywords
antigen
receptor
seq
cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532482A5 (cg-RX-API-DMAC7.html
Inventor
シュリゲル,パトリック
ジョーチュナー,アレクサンダー
Original Assignee
バイオセプター (オースト) プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021902832A external-priority patent/AU2021902832A0/en
Application filed by バイオセプター (オースト) プロプライエタリー・リミテッド filed Critical バイオセプター (オースト) プロプライエタリー・リミテッド
Publication of JP2024532482A publication Critical patent/JP2024532482A/ja
Publication of JP2024532482A5 publication Critical patent/JP2024532482A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP2024513926A 2021-09-01 2022-09-01 免疫活性を刺激するための方法および組成物 Pending JP2024532482A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021902832A AU2021902832A0 (en) 2021-09-01 Methods and compositions for stimulating immune activity
AU2021902832 2021-09-01
PCT/AU2022/051070 WO2023028657A1 (en) 2021-09-01 2022-09-01 Methods and compositions for stimulating immune activity

Publications (2)

Publication Number Publication Date
JP2024532482A true JP2024532482A (ja) 2024-09-05
JP2024532482A5 JP2024532482A5 (cg-RX-API-DMAC7.html) 2025-08-01

Family

ID=85410590

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024513926A Pending JP2024532482A (ja) 2021-09-01 2022-09-01 免疫活性を刺激するための方法および組成物
JP2024513973A Pending JP2024532489A (ja) 2021-09-01 2022-09-01 新規の機能不全p2x7結合剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024513973A Pending JP2024532489A (ja) 2021-09-01 2022-09-01 新規の機能不全p2x7結合剤

Country Status (8)

Country Link
US (2) US20240368282A1 (cg-RX-API-DMAC7.html)
EP (2) EP4395814A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024532482A (cg-RX-API-DMAC7.html)
CN (2) CN117813109A (cg-RX-API-DMAC7.html)
AU (2) AU2022341030A1 (cg-RX-API-DMAC7.html)
CA (2) CA3223079A1 (cg-RX-API-DMAC7.html)
MX (2) MX2023015469A (cg-RX-API-DMAC7.html)
WO (2) WO2023028657A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016100232A1 (en) * 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA3195512A1 (en) * 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス, インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター (オースト) プロプライエタリー・リミテッド 機能不全p2x7受容体に結合するためのキメラ抗原受容体
WO2024211413A2 (en) * 2023-04-05 2024-10-10 Arizona Board Of Regents On Behalf Of The University Of Arizona Trogocytosis in cancer cells and methods for treating cancer related thereto
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포
WO2025000037A1 (en) * 2023-06-30 2025-01-02 Biosceptre (Aust) Pty Ltd Molecules and methods for activating car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395832B1 (en) * 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
EP2516470B1 (en) * 2009-12-24 2018-02-07 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
CN107614528A (zh) * 2015-04-02 2018-01-19 生物权威(英国)有限公司 疼痛治疗
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109862883A (zh) * 2016-10-21 2019-06-07 生物权威(英国)有限公司 细胞毒性颗粒
AU2019275479B2 (en) * 2018-05-21 2022-12-08 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors with modified linker domains and uses thereof
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
MX2021011750A (es) * 2019-03-27 2021-12-10 Nat Res Council Canada Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system

Also Published As

Publication number Publication date
EP4395814A4 (en) 2025-09-03
WO2023028657A1 (en) 2023-03-09
CN117813109A (zh) 2024-04-02
AU2022335932A1 (en) 2023-11-30
MX2023015028A (es) 2024-02-16
US20240368282A1 (en) 2024-11-07
EP4395814A1 (en) 2024-07-10
MX2023015469A (es) 2024-01-19
WO2023028653A1 (en) 2023-03-09
JP2024532489A (ja) 2024-09-05
US20240376193A1 (en) 2024-11-14
EP4395813A1 (en) 2024-07-10
AU2022341030A1 (en) 2023-11-30
EP4395813A4 (en) 2025-07-09
CA3223086A1 (en) 2023-03-09
CN117881421A (zh) 2024-04-12
CA3223079A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
US20240368282A1 (en) Methods and compositions for stimulating immune activity
US20240018251A1 (en) Bcma-targeting single-domain antibody and use thereof
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体(car)構築物及びその使用
US20200062858A1 (en) Trispecific antigen binding proteins
US20250281611A1 (en) Novel cell therapy system
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
US20210179728A1 (en) Modified anti-sirpa antibodies and uses thereof
CN113784980B (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
KR20210150432A (ko) 인간화 항-dll3 키메라 항원 수용체 및 이의 용도
WO2023177974A2 (en) Anti-mesothelin antibodies and uses thereof
JP2026513651A (ja) Adgre2キメラ受容体nk細胞組成物及び使用方法
US20240207407A1 (en) Egfrviii binding proteins
JP2025529903A (ja) デルタ様リガンド3(dll3)に特異的な抗体およびキメラ抗原受容体
JP2024513485A (ja) 免疫細胞活性を制御する方法
WO2026061484A1 (en) NKp80-BINDING PROTEINS AND USES THEREOF
TW202305137A (zh) 靶向白蛋白的嵌合抗原受體及其使用方法
WO2025072871A2 (en) ANTI-SIRPα ANTIBODY COMPOSITIONS AND USES THEREOF
JP2025530110A (ja) 二重特異性ポリペプチド及びその使用
HK40120953A (en) Anti-mesothelin antibodies and uses thereof
WO2024206549A2 (en) Engineered immune cells and use thereof
CN117750963A (zh) 新的细胞疗法系统
AU2024306505A1 (en) Molecules and methods for activating car t cells
HK40056378B (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250724